Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats

Experimental Neurology

Volumn 213, Issue 1, 2008, Pages 196-201

  Copin, Jean Christophe ^a,b   Merlani, Paolo ^a   Sugawara, Taku ^c   Chan, Pak H ^d   Gasche, Yvan ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Ischemia; Matrix metalloproteinase; Thrombolysis; Tissue plasminogen activator

Indexed keywords

4 AMINOBENZOYLGLYCYLPROLINE DEXTRO LEUCINE DEXTRO ALANYLHYDROXAMATE; ALTEPLASE; HEMOGLOBIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; BRAIN EDEMA; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN PERFUSION; BRAIN SIZE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME INHIBITION; FIBRINOLYTIC THERAPY; GRAVITY; HEMISPHERE; HEMOGLOBIN DETERMINATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; RISK REDUCTION; SPRAGUE DAWLEY RAT; THERAPY DELAY; TREATMENT OUTCOME;

ANIMALS; BRAIN EDEMA; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENZYME INHIBITORS; INTRACRANIAL EMBOLISM; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, SPRAGUE-DAWLEY; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 49349107936     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.05.022     Document Type: Article

References (43)

1. Asahi M., Wang X., Mori T., Sumii T., Jung J.C., Moskowitz M.A., Fini M.E., and Lo E.H. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21 (2001) 7724-7732
2. Barber P.A., Zhang J., Demchuk A.M., Hill M.D., and Buchan A.M. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56 (2001) 1015-1020
3. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., and Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 (1986) 472-476
4. Busch E., Kruger K., and Hossmann K.A. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res. 778 (1997) 16-24
5. Castellanos M., Leira R., Serena J., Blanco M., Pedraza S., Castillo J., and Davalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35 (2004) 1671-1676
6. Castellanos M., Sobrino T., Millan M., Garcia M., Arenillas J., Nombela F., Brea D., Perez de la Ossa N., Serena J., Vivancos J., Castillo J., and Davalos A. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke. A Multicenter Confirmatory Study. Stroke 38 (2007) 1855-1859
7. del Zoppo G.J., Poeck K., Pessin M.S., Wolpert S.M., Furlan A.J., Ferbert A., Alberts M.J., Zivin J.A., Wechsler L., Busse O., et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32 (1992) 78-86
8. Emerich D.F., Dean III R.L., and Bartus R.T. The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct?. Exp. Neurol. 173 (2002) 168-181
9. Falo M.C., Fillmore H.L., Reeves T.M., and Phillips L.L. Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury. J. Neurosci. Res. 84 (2006) 768-781
10. Gasche Y., Copin J.C., Sugawara T., Fujimura M., and Chan P.H. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21 (2001) 1393-1400
11. Gasche Y., Fujimura M., Morita-Fujimura Y., Copin J.C., Kawase M., Massengale J., and Chan P.H. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J. Cereb. Blood Flow Metab. 19 (1999) 1020-1028
12. Gidday J.M., Gasche Y.G., Copin J.C., Shah A.R., Perez R.S., Shapiro S.D., Chan P.H., and Park T.S. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H558-568
13. Hacke W., Donnan G., Fieschi C., Kaste M., von Kummer R., Broderick J.P., Brott T., Frankel M., Grotta J.C., Haley Jr. E.C., Kwiatkowski T., Levine S.R., Lewandowski C., Lu M., Lyden P., Marler J.R., Patel S., Tilley B.C., Albers G., Bluhmki E., Wilhelm M., and Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
14. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G., Schneider D., Diez-Tejedor E., and Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352 (1998) 1245-1251
15. Hamann G.F., Okada Y., Fitridge R., and del Zoppo G.J. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26 (1995) 2120-2126
16. Heo J.H., Lucero J., Abumiya T., Koziol J.A., Copeland B.R., and del Zoppo G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 19 (1999) 624-633
17. Justicia C., Panes J., Sole S., Cervera A., Deulofeu R., Chamorro A., and Planas A.M. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab. 23 (2003) 1430-1440
18. Kelly M.A., Shuaib A., and Todd K.G. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 200 (2006) 38-49
19. Lapchak P.A. The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator. Exp Neurol 205 (2007) 407-413
20. Lapchak P.A., Chapman D.F., and Zivin J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31 (2000) 3034-3040
21. Latour L.L., Kang D.W., Ezzeddine M.A., Chalela J.A., and Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 56 (2004) 468-477
22. Lehoux S., Lemarie C.A., Esposito B., Lijnen H.R., and Tedgui A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 109 (2004) 1041-1047
23. Montaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribo M., Quintana M., and Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107 (2003) 598-603
24. Neumann-Haefelin C., Brinker G., Uhlenkuken U., Pillekamp F., Hossmann K.A., and Hoehn M. Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI investigation in rat brain. Stroke 33 (2002) 1392-1398
25. Niessen F., Hilger T., Hoehn M., and Hossmann K.A. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke 34 (2003) 2019-2024
26. NINDS-group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333 (1995) 1581-1587
27. Odake S., Morita Y., Morikawa T., Yoshida N., Hori H., and Nagai Y. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids. Biochem Biophys Res Commun 199 (1994) 1442-1446
28. Pfefferkorn T., and Rosenberg G.A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34 (2003) 2025-2030
29. Reeves T.M., Prins M.L., Zhu J., Povlishock J.T., and Phillips L.L. Matrix metalloproteinase inhibition alters functional and structural correlates of deafferentation-induced sprouting in the dentate gyrus. J Neurosci 23 (2003) 10182-10189
30. Ribo M., Molina C.A., Rovira A., Quintana M., Delgado P., Montaner J., Grive E., Arenillas J.F., and Alvarez-Sabin J. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 36 (2005) 602-606
31. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., and Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29 (1998) 1020-1030
32. Rosell A., Ortega-Aznar A., Alvarez-Sabin J., Fernandez-Cadenas I., Ribo M., Molina C.A., Lo E.H., and Montaner J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37 (2006) 1399-1406
33. Rosenberg G.A., Cunningham L.A., Wallace J., Alexander S., Estrada E.Y., Grossetete M., Razhagi A., Miller K., and Gearing A. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893 (2001) 104-112
34. Rosenberg G.A., Estrada E.Y., and Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29 (1998) 2189-2195
35. Schellinger P.D., Fiebach J.B., Mohr A., Ringleb P.A., Jansen O., and Hacke W. Thrombolytic therapy for ischemic stroke-a review. Part I-Intravenous thrombolysis. Crit Care Med 29 (2001) 1812-1818
36. Standefer J.C., and Vanderjagt D. Use of tetramethylbenzidine in plasma hemoglobin assay. Clin Chem 23 (1977) 749-751
37. Sumii T., and Lo E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33 (2002) 831-836
38. von Kummer R., and Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 23 (1992) 646-652
39. Wang C.X., Yang T., and Shuaib A. An improved version of embolic model of brain ischemic injury in the rat. J Neurosci Methods 109 (2001) 147-151
40. Zhang Z., Zhang L., Yepes M., Jiang Q., Li Q., Arniego P., Coleman T.A., Lawrence D.A., and Chopp M. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106 (2002) 740-745
41. Zhang Z., Zhang R.L., Jiang Q., Raman S.B., Cantwell L., and Chopp M. A new rat model of thrombotic focal cerebral ischemia. J. Cereb. Blood Flow Metab. 17 (1997) 123-135
42. Zhang L., Zhang Z.G., Zhang C., Zhang R.L., and Chopp M. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model. Stroke 35 (2004) 2890-2895
43. Zhang L., Zhang Z.G., Zhang R.L., Lu M., Adams J., Elliott P.J., and Chopp M. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32 (2001) 2926-2931